← Back to headlines
Nuvation Bio and Eisai Receive EMA Validation for Taletrectinib
Nuvation Bio Inc. (NUVB) and Eisai have received EMA (European Medicines Agency) validation for their drug Taletrectinib, moving it forward in the regulatory process.
1 Apr, 11:07 — 1 Apr, 11:07
Sources
Showing 1 of 1 sources
